Correlates of Bone Mineral Density in Elderly Patients with Hip Fractures

1995 ◽  
Vol 9 (6) ◽  
pp. 470-475 ◽  
Author(s):  
Douglas R. Dirschl ◽  
Richard C. Henderson ◽  
Ward S. Oakley
Keyword(s):  
Bone Mineral Density ◽  
Elderly Patients ◽  
Bone Mineral ◽  
Hip Fractures ◽  
Mineral Density

scholarly journals Effects of 3-year GH replacement therapy on bone mineral density in younger and elderly adults with adult-onset GH deficiency

2012 ◽  
Vol 166 (2) ◽  
pp. 181-189 ◽  
Author(s):  
Mariam Elbornsson ◽  
Galina Götherström ◽  
Celina Franco ◽  
Bengt-Åke Bengtsson ◽  
Gudmundur Johannsson ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Elderly Patients ◽  
Bone Mineral ◽  
The Elderly ◽  
Marginal Effect ◽  
Adult Onset ◽  
Mineral Density ◽  
Gh Replacement ◽  
Femur Neck

ObjectiveLittle is known of the effects of long-term GH replacement on bone mineral content (BMC) and bone mineral density (BMD) in elderly GH-deficient (GHD) adults.Design/patients/methodsIn this prospective, single-center, open-label study, the effects of 3-year GH replacement were determined in 45 GHD patients >65 years and in 45 younger control GHD patients with a mean age of 39.5 (s.e.m.1.1) years. All patients had adult-onset disease and both groups were comparable in terms of number of anterior pituitary hormonal deficiencies, gender, body mass index, and waist:hip ratio.ResultsThe mean maintenance dose of GH was 0.24 (0.02) mg/day in the elderly patients and 0.33 (0.02) mg/day in the younger GHD patients (P<0.01). The 3 years of GH replacement induced a marginal effect on total body BMC and BMD, whereas femur neck and lumbar (L2–L4) spine BMC and BMD increased in both the elderly and the younger patients. The treatment response in femur neck BMC was less marked in the elderly patients (P<0.05 vs younger group). However, this difference disappeared after correction for the lower dose of GH in the elderly patients using an analysis of covariance. There were no between-group differences in responsiveness in BMC or BMD at other skeletal locations.ConclusionsThis study shows that GH replacement increases lumbar (L2–L4) spine and femur neck BMD and BMC in younger as well as elderly GHD patients. This supports the notion that long-term GH replacement is also useful in elderly GHD patients.

scholarly journals Link between vitamin B12, type 2 diabetes mellitus, and bone mineral density in elderly patients

2015 ◽  
Vol 6 (4) ◽  
pp. 120-124 ◽  
Author(s):  
Moatassem S. Amer ◽  
Randa Ali-Labib ◽  
Tamer M. Farid ◽  
Doha Rasheedy ◽  
Mohammad F. Tolba
Keyword(s):  
Diabetes Mellitus ◽  
Bone Mineral Density ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Elderly Patients ◽  
Vitamin B12 ◽  
Bone Mineral ◽  
Mineral Density

The Clinical Use of Denosumab for the Management of Low Bone Mineral Density in Postmenopausal Women

2012 ◽  
Vol 25 (3) ◽  
pp. 310-318 ◽  
Author(s):  
Kira B. Harris ◽  
Kimberly L. Nealy ◽  
Delilah J. Jackson ◽  
Phillip L. Thornton
Keyword(s):  
Bone Mineral Density ◽  
Postmenopausal Women ◽  
Bone Mineral ◽  
Hip Fractures ◽  
Nuclear Factor Κb ◽  
Bisphosphonate Therapy ◽  
Mineral Density ◽  
Osteoporosis Therapy ◽  
Cost Of Health Care ◽  
Therapy Studies

Osteoporosis is a leading cause of debility and declining quality of life in postmenopausal women worldwide. Treatment of osteoporosis has been ubiquitous throughout the developed world since the mid-1990s, most notably with the introduction of bisphosphonates in 1995. Nonetheless, the incidence of hip fractures increased by 25% between 1990 and 2000, despite advances in osteoporosis therapy. Studies indicate that bone density increases over the first 3 years of bisphosphonate therapy and then plateaus or perhaps even declines, placing these patients at greater risk of fracture. Since hip fractures are associated with increased morbidity, mortality, and increased cost of health care, improvements in treating osteoporosis are critical. Denosumab is a novel monoclonal antibody targeted against the receptor activator of nuclear factor-κB ligand (RANKL) that inhibits osteoclast activity. Initial data suggest that denosumab increases bone mineral density for greater than 3 years. Of greater importance, denosumab has been shown to decrease vertebral fractures by 68%, nonvertebral fractures by 19%, and hip fractures by 42% for at least 36 months. Data also indicate that the safety profile of denosumab is equivalent to other drugs used in osteoporosis management, but potential risks of immunosuppression and cancer have been hypothesized.

The Relationship between Hip Fracture and Bone Mineral Density in Elderly Patients

2010 ◽  
Vol 45 (3) ◽  
pp. 228 ◽  
Author(s):  
Hwa Jae Jeong ◽  
Jae-Yeol Choi ◽  
Jinmyung Lee ◽  
Kyubo Choi ◽  
Byeongsam Jeon
Keyword(s):  
Bone Mineral Density ◽  
Hip Fracture ◽  
Elderly Patients ◽  
Bone Mineral ◽  
Mineral Density ◽  
The Relationship

scholarly journals Hip fractures following denosumab discontinuation: three clinical cases reports

2019 ◽  
Vol 112 (11) ◽  
pp. 472-475 ◽  
Author(s):  
Manuel Sosa Henríquez ◽  
María Jesús Gómez de Tejada Romero ◽  
María Escudero-Socorro ◽  
Oscar Torregrosa Suau
Keyword(s):  
Bone Mineral Density ◽  
Bone Mineral ◽  
Hip Fractures ◽  
Vertebral Fractures ◽  
Femoral Fractures ◽  
Significant Loss ◽  
Mineral Density ◽  
Denosumab Treatment ◽  
Multiple Vertebral Fractures ◽  
Clinical Cases

Summary A significant loss of bone mineral density and the appearance of multiple vertebral fractures after discontinuation of denosumab treatment have been described. To date, no hip fractures have been reported. We present three cases of patients who suffered femoral fractures after denosumab suppression.

Hip fractures and femoral bone mineral density in male former elite athletes

Bone ◽  
2010 ◽  
Vol 46 (2) ◽  
pp. 330-335 ◽  
Author(s):  
Jyrki A. Kettunen ◽  
Olli Impivaara ◽  
Urho M. Kujala ◽  
Miika Linna ◽  
Juhani Mäki ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Bone Mineral ◽  
Hip Fractures ◽  
Elite Athletes ◽  
Femoral Bone ◽  
Mineral Density ◽  
Femoral Bone Mineral Density ◽  
Former Elite Athletes

scholarly journals Effect of vitamin D on bone mineral density of elderly patients with osteoporosis responding poorly to bisphosphonates

2002 ◽  
Vol 3 (1) ◽  
Author(s):  
George A Heckman ◽  
Alexandra Papaioannou ◽  
Rolf J Sebaldt ◽  
George Ioannidis ◽  
Annie Petrie ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Vitamin D ◽  
Elderly Patients ◽  
Bone Mineral ◽  
Mineral Density
Sign in / Sign up

Export Citation Format

Share Document